More Cambium Bio Ltd news
Cambium Bio LtdASX: CMB

Regeneus to be granted new key Progenza patent in U.S.

Mar 22, 2020 at 11:03 PM EDT · Issued by Cambium Bio Ltd

Filed with ASX · Mar 22, 2020 at 11:03 PM EDT · 2 pages · English

On 6ix: 6ix.com/news/regeneus-to-be-granted-new-key-progenza-patent-in-us

Cambium Bio Ltd on 6ix

Story so far

  • Positive results for Progenza in treating neuropathic painJul 23, 2019
  • Progenza patent to grant in EuropeOct 18, 2018
  • US Patent Office to allow key patent for ProgenzaJul 10, 2018

Earlier from Cambium Bio

  • Regeneus receives A$1.6M milestone payment from KyoceraMar 19, 2020
  • Regeneus signs MOU with Kyocera CorporationMar 1, 2020
  • Half-Year Results & Business UpdateFeb 28, 2020
  • Directors provide $4m loan facilityFeb 28, 2020
  • AGC Agreement termination paves way for commercial partnerDec 19, 2019

Later from Cambium Bio

  • Appendix 4C UpdatedMay 5, 2020
  • Kyocera completes Progenza Due DiligenceMay 17, 2020
  • Progenza OA Kyocera negotiations updateJul 27, 2020
  • Regeneus and Kyocera sign Progenza OA dealAug 11, 2020
  • US Patent for SygenusAug 18, 2020
All Cambium Bio news releases↗

Follow Cambium Bio into a list and get an email when it puts out news.

Follow Cambium Bio
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer